Rapt Therapeutics (RAPT) Stock Price, News & Analysis

Company Overview

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma. By selectively blocking CCR4-mediated migration of pathogenic T cells to inflamed tissues, RPT193 aims to reduce disease activity without broad immunosuppression. RAPT is also advancing discovery-stage programs against additional chemokine receptors involved in tissue inflammation, including efforts in ulcerative colitis and other indications.

Since its initial public offering in 2020, RAPT has expanded its operations across the United States, leveraging partnerships and collaborations to extend its global reach. The company maintains research and development facilities in San Diego and engages with clinical sites worldwide to advance its pipeline.

Under the leadership of Chief Executive Officer John C. Huggins, RAPT’s management team brings extensive experience in immunology, drug discovery and clinical development. The organization is guided by a board of directors and scientific advisors with deep expertise in translational research and biopharmaceutical innovation.

Key Stats

• Today's Range: $58.02 to $58.02
• 50-Day Range: $57.61 to $58.02
• 52-Week Range: $5.67 to $58.02
• Volume: N/A
• Average Volume: 4.25 million shs
• Market Capitalization: $1.61 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.80
• Consensus Rating: Hold

Rapt Therapeutics Stock Analysis - MarketRank™

Rapt Therapeutics scored higher than 3% of companies evaluated by MarketBeat, and ranked 890th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Rapt Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 8 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Rapt Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Rapt Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rapt Therapeutics are expected to grow in the coming year, from ($2.14) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rapt Therapeutics is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rapt Therapeutics is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rapt Therapeutics has a P/B Ratio of 5.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for RAPT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rapt Therapeutics does not currently pay a dividend.

Dividend Growth

Rapt Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for RAPT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rapt Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.36% of the stock of Rapt Therapeutics is held by insiders.

Percentage Held by Institutions

99.09% of the stock of Rapt Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/06/2025
• Today: 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RAPT
• CIK: 1673772
• Web: www.rapt.com
• Phone: (650) 489-9000
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Rapt Therapeutics: $57.80
• High Price Target: $58.00
• Low Price Target: $57.00
• Potential Upside/Downside: -0.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.81%
• Return on Assets: -54.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.04
• Quick Ratio: 12.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.51 per share
• Price / Book: 5.04

Miscellaneous

• Outstanding Shares: 27,711,000
• Free Float: 27,057,000
• Market Cap: $1.61 billion
• Optionable: Optionable
• Beta: 0.49